Your gift is lifesaving for those facing cancer, like Aleta and her grandson. Start a monthly gift today, and your first three months will be MATCHED.
The value must be greater than or equal to $5
The value must be lesser than $1M
Your gift is 100% tax deductible.
Español
PDFs by language
Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Call us at 1-800-227-2345
Available any time of day or night
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
About 5 to 10 million people are thought to have been exposed to DES (diethylstilbestrol) during pregnancy from 1940 to 1971. Get up-to-date information on cancer risk and other potential health problems from DES exposure.
DES (diethylstilbestrol) is a man-made (synthetic) form of the hormone estrogen.
Doctors prescribed DES from 1940 until 1971 to help some pregnant women avoid problems with pregnancy. Though it was found to be ineffective, it was given to millions of women in the United States during this time.
In 1971, research came out that exposure to DES in the womb was linked with a rare type of cancer of the cervix and vagina. Soon after, the US Food and Drug Administration (FDA) advised doctors to stop prescribing it during pregnancy. A campaign was also started to tell the public about the problems DES could cause, but many people who were exposed to DES still don’t know it.
Since that time, research has shown that people exposed to DES may be at risk for several health problems.
About 5 to 10 million people are thought to have been exposed to DES during pregnancy. This includes:
Only those children who were in the womb at the time their mothers took DES were exposed to it. Brothers or sisters from pregnancies during which DES was not taken were not exposed.
Any woman who was pregnant between 1940 and 1971 and had problems during her pregnancy or a previous pregnancy may have been given DES or another estrogen-like drug. But many women don’t know if they got DES while they were pregnant.
There are no medical tests to determine if you’ve been exposed to DES. If you think you or your mother took a hormone like DES during pregnancy, you can try to contact the hospital where you were born to ask if there is any record that your mother was given DES. Mothers and children have a right to see any of their remaining medical records.
Unfortunately, finding medical records after such a long time may not be possible. Most hospitals and doctors’ offices do not keep medical charts or records beyond a few years.
The county medical society or health department may be able to tell you where the records are, if they still exist. If you know where the prescription was filled, you might want to ask there, but many chain drugstores only keep records up to 10 years.
If you are able to get records, it may help to know that DES was sold under many different names. You can find a list of DES brand names at https://desaction.org/brand-names/.
Women who were given DES during pregnancy might be at higher risk for certain health issues.
Women who took DES appear to have an increased risk of breast cancer. Most research suggests that DES mothers have about a 30% higher risk of breast cancer than other women.
When looking at breast cancer risk during a woman’s lifetime, this means about 1 out of 6 women who took DES during pregnancy will get breast cancer, as opposed to about 1 out of 8 women who were not exposed to DES. Of course, many other factors affect breast cancer risk as well.
There are no other known health effects among DES mothers.
Women whose mothers took DES while pregnant with them may be at higher risk for some types of cancer.
DES is linked to a rare cancer called clear cell adenocarcinoma (CCA) in a very small number of daughters of women who used DES during pregnancy. While risk of this cancer is increased among DES daughters, it is still very rare.
Many studies have looked at breast cancer risk in DES daughters. Some have found a slightly increased risk of breast cancer among DES daughters, but others have found that that the risk isn’t any higher.
Some research suggests that DES daughters might be more likely to develop pancreatic cancer than women in general.
About 4% of DES daughters develop abnormal cells in the cervix and vagina, also called cervical precancers. These are not cancers, but they might develop into cancer if not treated. This risk is about twice as high as in women not exposed to DES.
The following are other potential health problems for women whose mothers took DES while pregnant with them.
DES daughters are more likely to experience problems getting pregnant or during pregnancy, including premature births, ectopic pregnancies, and miscarriages. However, at this time, DES daughters are largely past their reproductive years.
One study found that DES daughters were more likely to be diagnosed with depression. However, later studies found no increased risk of depression among DES daughters.
DES daughters are at a higher risk of heart problems, including high cholesterol, high blood pressure, and heart disease.
In the past, additional tests such as yearly pelvic exams were recommended to screen for clear cell carcinoma and other problems, but it’s not clear until what age these screenings should continue. Ask your health care team if they recommend any additional exams or tests.
The following are potential health problems for men whose mothers took DES while pregnant with them.
DES sons are more likely to have genital abnormalities, like undescended testicles or cysts in the epididymis. They also may be at a higher risk for testicle inflammation and infection.
DES sons don’t seem to have more fertility problems than other men. Studies have been done to see if they are at a higher risk of testicular cancer, but the results are unclear.
DES sons are at a higher risk of heart problems, including high cholesterol, high blood pressure, and heart disease.
There are no special screenings or tests recommended for DES sons, but they
should tell their doctors about their exposure and get regular exams. DES sons may want to talk to their doctors about whether they should examine their testicles regularly.
DES grandchildren are the children of DES sons or DES daughters. They are also being studied because researchers have found that some gene changes caused by DES in DES sons and daughters might be passed on to their children.
Some research has suggested that DES granddaughters might begin their menstrual periods at later ages and be more likely to have irregular menstrual cycles. They might also have a higher risk of infertility and preterm birth than other women. But these findings are based on small numbers of events, and more research is needed.
Research is ongoing to determine whether DES grandchildren are at a higher risk for any other health problems.
Researchers around the world continue to study people who have been exposed to DES, their children, and their grandchildren to look for possible health effects. Some people known to have been exposed to DES are being watched in the National Cancer Institute’s DES Follow-up Study, which was started in 1992.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
Hoover RN, Hyer M, Pfeiffer RM, et al. Adverse health outcomes in women exposed in utero to diethylstilbestrol. NEJM. 2011;365(14):1304–1314.
Huo D, Anderson D, Palmer JR, Herbst AL. Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up. Gynec Oncol. 2017;146(3):566–571
Kaufman RH, Adam E. Findings in female offspring of women exposed in utero to diethylstilbestrol. Obstet Gynecology. 2002;99(2):197–200.
National Cancer Institute. Diethylstilbestrol (DES) Exposure and Cancer. 2021. Accessed at https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/des-fact-sheet on December 17, 2024.
O’Reilly EJ, Mirzaei F, Forman MR, Ascherio A. Diethylstilbestrol exposure in utero and depression in women. Am J Epidemiol. 2010;171(8):876–882.
Palmer JR, Herbst AL, Noller KL, et al. Urogenital abnormalities in men exposed to diethylstilbestrol in utero: A cohort study. Environ Health. 2009; 8:37.
Palmer JR, Wise LA, Hatch EE, et al. Prenatal diethylstilbestrol exposure and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(8):1509–1514.
Sato K, Fukata H, Kogo Y, et al. Neonatal exposure to diethylstilbestrol alters expression of DNA methyltransferases and methylation of genomic DNA in the mouse uterus. Endocrine Journal. 2009;56(1):131–139.
Titus L, Hatch EE, Drake KM, et al. Reproductive and hormone-related outcomes in women whose mothers were exposed in utero to diethylstilbestrol (DES): A report from the US National Cancer Institute DES Third Generation Study. Reprod Toxicol. 2019; 84:32–38.
Titus-Ernstoff L, Hatch EE, Hoover RN, et al. Long-term cancer risk in women given diethylstilbestrol (DES) during pregnancy. British J Canc. 2001;84(1):126–133.
Titus-Ernstoff L, Perez K, Hatch EE, et al. Psychosexual characteristics of men and women exposed prenatally to diethylstilbestrol. Epidemiol. 2003;14(2):155–160.
Titus-Ernstoff L, Troisi R, Hatch EE, et al. Menstrual and reproductive characteristics of women whose mothers were exposed in utero to diethylstilbestrol (DES). Int J Epidemiol. 2006;35(4):862–868.
Troisi R, Hatch EE, Titus L, et al. Prenatal diethylstilbestrol exposure and cancer risk in women. Environmental and Molecular Mutagenesis. 2019; 60(5):395–403.
Troisi R, Hyer M, Hatch EE, et al. Medical conditions among adult offspring prenatally exposed to diethylstilbestrol. Epidemiol. 2013; 24(3):430–438.
Troisi R, Hyer M, Titus L, et al. Prenatal diethylstilbestrol exposure and risk of diabetes, gallbladder disease, and pancreatic disorders and malignancies. J Development Orig Health Dis. 2021;12(4):619–626.
Troisi R, Palmer JR, Hatch EE, et al. Gender identity and sexual orientation identity in women and men prenatally exposed to diethylstilbestrol. Arch Sexual Behavior. 2020;49(2):447–454.
Troisi R, Titus L, Hatch EE, et al. A prospective cohort study of prenatal diethylstilbestrol exposure and cardiovascular disease risk. J Clin Endocrinol Metabolism. 2018;103(1):206–212.
Verloop J, van Leeuwen FE, Helmerhorst TJ, van Boven HH, Rookus MA. Cancer risk in DES daughters. Canc Causes Control. 2010;21(7):999–1007.
Last Revised: January 13, 2025
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.
If this was helpful, donate to help fund patient support services, research, and cancer content updates.